Company Overview - Aonong Biological Technology Group Co., Ltd. is located in Zhangzhou, Fujian Province, and was established on April 26, 2011. The company was listed on September 26, 2017. Its main business includes feed, pig farming, food, and trade [1][2]. - The revenue composition of Aonong Biological is as follows: feed industry 66.22%, pig farming 20.95%, food 12.60%, and other 0.22% [1]. Financial Performance - For the period from January to September 2025, Aonong Biological achieved operating revenue of 6.335 billion yuan, a year-on-year decrease of 8.52%. However, the net profit attributable to the parent company was 414 million yuan, reflecting a significant year-on-year increase of 150.54% [2]. - Since its A-share listing, Aonong Biological has distributed a total of 180 million yuan in dividends, with no dividends distributed in the past three years [3]. Stock Performance - As of October 29, Aonong Biological's stock price increased by 2.37%, reaching 5.18 yuan per share, with a trading volume of 104 million yuan and a turnover rate of 1.29%. The total market capitalization is 13.483 billion yuan [1]. - Year-to-date, Aonong Biological's stock price has risen by 46.33%, with a 3.19% increase over the last five trading days, a 4.65% increase over the last 20 days, and a 34.90% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 27, where it recorded a net purchase of 14.9985 million yuan [1]. Shareholder Information - As of September 30, Aonong Biological had 74,900 shareholders, an increase of 62.69% compared to the previous period. The average number of circulating shares per shareholder is 21,340, which is a decrease of 38.53% [2].

Market Overview - The feed sector experienced a decline of 1.0% on October 28, with Lu Si Co. leading the drop [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Individual Stock Performance - Zhongchong Co. (002891) saw a closing price of 56.36, with an increase of 3.49% and a trading volume of 87,800 shares, totaling 492 million yuan [1] - Guibao Pet (301498) closed at 72.62, up 3.04%, with a trading volume of 64,800 shares and a total transaction value of 467 million yuan [1] - Lu Si Co. (920419) led the decline with a closing price of 17.56, down 2.71%, and a trading volume of 17,200 shares, amounting to 30.36 million yuan [2] - Haida Group (002311) closed at 56.69, down 2.56%, with a trading volume of 106,400 shares and a total transaction value of 604 million yuan [2] Capital Flow Analysis - The feed sector experienced a net outflow of 101 million yuan from institutional investors, while retail investors saw a net inflow of 80.56 million yuan [2] - The main capital inflow and outflow for selected stocks showed varied trends, with Zhongchong Co. having a net inflow of 23.57 million yuan from institutional investors [3] - Haida Group had a net inflow of 15.68 million yuan from institutional investors, while experiencing a net outflow of 2.16 million yuan from retail investors [3]

Core Viewpoint - Aonong Bio (603363.SH) reported a decline in revenue for the first three quarters of 2025, but achieved a significant turnaround in net profit compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 6.335 billion yuan, representing a year-on-year decrease of 8.52% [1] - The net profit attributable to shareholders was 414 million yuan, a recovery from a loss of 819 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.16 yuan [1]

Group 1 - The core point of the article is that Aonong Biological (SH 603363) reported a decline in revenue and net profit for the first three quarters of 2025, indicating a challenging financial environment for the company [1] Group 2 - Aonong Biological's revenue for the first three quarters of 2025 was approximately 6.335 billion yuan, representing a year-on-year decrease of 8.52% [1] - The net profit attributable to shareholders of the listed company was around 414 million yuan, with a basic earnings per share of 0.16 yuan [1] - As of the report date, Aonong Biological's market capitalization stood at 13.4 billion yuan [1]

证券代码：603363 证券简称：傲农生物 公告编号：2025-101 福建傲农生物科技集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 12 日（星期三）至 11 月 18 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 anzq@aonong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 福建傲农生物科技集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日在上海证券交易所网站（www.sse.com.cn）披露公司《2025 年第三季度 报告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财 务状况，公司计划于 2025 年 11 月 19 日（星期三）15:00-16:00 举行 2025 年第三 ...

证券代码：603363 证券简称：傲农生物 公告编号：2025-102 福建傲农生物科技集团股份有限公司 2025 年 9 月公司担保情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、担保情况概述 福建傲农生物科技集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 3 月 28 日召开的第四届董事会第十二次会议和 2025 年 4 月 14 日召开的 2025 年第二次临时股东大会审议通过了《关于 2025 年度为产业链合作伙伴提供 担保的议案》、《关于 2025 年度公司及下属子公司相互提供担保的议案》，内 容包括： 1、同意公司及下属子公司 2025 年度为公司及下属子公司的下游客户、产业 链供应商、公司养殖放养业务的合作养户等产业链合作伙伴提供不超过 8 亿元的 担保。 2、同意公司及下属全资、控股子公司在 2025 年度继续相互提供担保，其中 公司为下属资产负债率低于 70%的子公司提供最高担保金额 15 亿元；公司为下 属资产负债率 70%以上的子公司提供最高担保金额 15 亿元；公司下属 ...

证券代码：603363 证券简称：傲农生物 公告编号：2025-100 （一）审议通过《公司 2025 年第三季度报告》 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 本议案已经第四届董事会审计委员会第十四次会议审议通过。 具体内容详见公司同日于上海证券交易所网站（www.sse.com.cn）披露的《公 司 2025 年第三季度报告》。 （二）审议通过《关于设立福建傲农在线网络科技等全资子公司暨构建福 建省餐饮生鲜猪、牛、羊肉供应链体系的议案》 福建傲农生物科技集团股份有限公司 第四届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 福建傲农生物科技集团股份有限公司（以下简称"公司"）第四届董事会第 十九次会议于 2025 年 10 月 27 日在公司会议室以现场会议与通讯会议相结合的 方式召开，会议通知和材料已于 2025 年 10 月 24 日以专人送达、电子邮件、短 信或即时通讯工具等方式发出。本次会议由董事长苏明城先生召集和主持，会议 应出席董事 9 人 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥2,378,228,038.62, representing a year-on-year increase of 4.79%[4] - The total profit for the year-to-date period was ¥411,906,851.31, showing a year-on-year decrease of 8.52%[4] - The net profit attributable to shareholders for the third quarter was ¥53,132,187.70, while the year-to-date net profit was ¥413,933,328.13[4] - Total operating revenue for the first three quarters of 2025 was CNY 6,335,161,290.25, a decrease of 8.5% compared to CNY 6,925,141,428.12 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was CNY 439,170,633.46, a significant recovery from a net loss of CNY 953,197,224.77 in the same period of 2024[19] - The company reported an operating profit of CNY 400,203,260.86 for the first three quarters of 2025, compared to an operating loss of CNY 842,841,306.91 in the previous year[19] - Basic earnings per share for the first three quarters of 2025 were CNY 0.16, compared to a loss of CNY 0.94 in the same period of 2024[20] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was negative at -¥291,468,594.15, a decrease of 287.60% compared to the previous year[5] - The company's cash and cash equivalents were reported at CNY 696.90 million, down from CNY 1.38 billion, indicating a significant decrease of approximately 49.6%[14] - The company's total current assets amounted to approximately CNY 3.52 billion, a decrease from CNY 3.70 billion as of December 31, 2024, representing a decline of about 4.8%[14] - Cash inflow from operating activities totaled $6,183,352,836.02, a decrease of 15.7% compared to $7,334,289,947.79 in the previous period[23] - Net cash outflow from operating activities was $291,468,594.15, contrasting with a net inflow of $155,362,935.60 previously[23] - The ending cash and cash equivalents balance was $353,065,577.53, slightly up from $335,867,519.81 at the end of the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥9,148,144,968.13, a decrease of 3.77% from the end of the previous year[5] - The total assets decreased to CNY 9,148,144,968.13 from CNY 9,506,097,034.21 year-over-year[16] - Total liabilities decreased to CNY 5,362,979,574.42 from CNY 6,444,948,812.96 year-over-year[16] - The company's fixed assets were valued at CNY 3.17 billion, down from CNY 3.40 billion, indicating a decrease of about 6.8%[14] - Long-term equity investments slightly decreased to CNY 121.56 million from CNY 125.55 million, a decline of approximately 3.2%[14] - The company’s long-term borrowings increased to CNY 1,586,852,473.04 from CNY 1,462,234,553.47 year-over-year[16] - The company’s total equity increased to CNY 3,785,165,393.71 from CNY 3,061,148,221.25 year-over-year[16] Shareholder Structure - The company has a significant shareholder structure with the top 10 shareholders holding a total of 1,267,995,301 shares, indicating a concentrated ownership[12] - The company has established consistent action relationships among several major shareholders, which may influence future strategic decisions[12] Non-Recurring Items and Restructuring - Non-recurring gains and losses for the current period totaled ¥84,415,557.50, with significant contributions from debt restructuring gains[7] - The company has undergone bankruptcy restructuring, which has alleviated operational burdens and reduced interest expenses significantly[8] - The increase in equity is attributed to the net profit growth and capital reserve increase from debt restructuring[8] Inventory and Receivables - Accounts receivable increased to CNY 706.78 million, compared to CNY 393.06 million in the previous period, reflecting an increase of about 79.9%[14] - Inventory levels rose to CNY 887.77 million, up from CNY 816.94 million, marking an increase of approximately 8.7%[14] - The company reported a total of CNY 898.31 million in other receivables, an increase from CNY 739.10 million, representing an increase of about 21.5%[14] - The company's production biological assets increased to CNY 318.67 million, compared to CNY 213.46 million, reflecting a growth of approximately 49.3%[14] Cash Flow from Investing and Financing Activities - Cash outflow from investing activities amounted to $198,360,042.39, down from $236,521,582.13, resulting in a net cash outflow of $133,607,659.96 from investing activities[24] - Total cash inflow from financing activities was $302,194,811.68, significantly lower than $835,829,180.76 in the prior period[24] - Net cash outflow from financing activities reached $353,526,276.38, compared to a net inflow of $50,378,894.08 previously[24] - The company reported a significant increase in cash received from the disposal of fixed assets, totaling $2,561,701.70 compared to $151,529,710.59 previously[23] - Cash received from investment activities was $64,752,382.43, a decrease from $214,636,632.20 in the previous period[23] - The company experienced a decrease in cash received from the absorption of investments, totaling $18,044,320.00 compared to $33,054,700.00 previously[24] Accounting Standards - The company will not apply new accounting standards starting from 2025[25]

Market Overview - The feed sector increased by 1.16% on October 27, with Jin Xin Nong leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Individual Stock Performance - Jin Xin Nong (002548) closed at 4.80, up 5.49% with a trading volume of 369,000 shares and a turnover of 173 million yuan [1] - Tian Kang Biological (002100) closed at 7.89, up 5.34% with a trading volume of 506,600 shares [1] - Tian Ma Technology (603668) closed at 14.06, up 4.15% with a trading volume of 218,000 shares and a turnover of 302 million yuan [1] - Ao Nong Biological (603363) closed at 5.16, up 4.03% with a trading volume of 1,878,500 shares and a turnover of 451 million yuan [1] - Other notable stocks include Bangtai Technology (603151) at 26.26, up 1.70%, and Hai Da Group (002311) at 58.18, up 0.97% [1] Capital Flow Analysis - The feed sector saw a net inflow of 132 million yuan from institutional investors, while retail investors experienced a net outflow of 148 million yuan [2] - The main capital inflow and outflow for key stocks are as follows: - Ao Nong Biological: Net outflow of 40.5 million yuan from main capital [3] - Tian Ma Technology: Net inflow of 34.8 million yuan from main capital [3] - Tian Kang Biological: Net inflow of 32.8 million yuan from main capital [3] - Hai Da Group: Net inflow of 30.4 million yuan from main capital [3]

Core Insights - The feed sector experienced a slight decline of 0.17% on October 24, with Tianma Technology leading the losses [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Feed Sector Performance - Zhongchong Co., Ltd. (002891) saw a closing price of 54.36, with an increase of 3.74% and a trading volume of 96,700 shares, amounting to a transaction value of 526 million yuan [1] - Other notable performers included Boen Group (001366) with a closing price of 13.03, up 0.77%, and Petty Co., Ltd. (300673) at 17.42, up 0.40% [1] - Tianma Technology (603668) led the declines with a closing price of 13.50, down 4.66%, and a trading volume of 222,500 shares, resulting in a transaction value of 309 million yuan [2] Capital Flow Analysis - The feed sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 97.74 million yuan [2] - The capital flow for individual stocks showed that Zhongchong Co., Ltd. had a net inflow of 12.28 million yuan from institutional investors, while it faced a net outflow of 36.39 million yuan from retail investors [3] - Other stocks like He Feng Co., Ltd. (60360a) and Boen Group (001366) also showed mixed capital flows, with varying degrees of net inflows and outflows from different investor categories [3]